I-Mab - ADR Stock

$5.18

7.47% yesterday

Nasdaq, Aug 26, 10:00 pm CET

ISIN

US44975P1030

Symbol

IMAB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

I-Mab - ADR Stock price

$5.18

-25.01 82.84% 5Y

Nasdaq, Closing price Tue, Aug 26 2025

+0.36 7.47%

ISIN

US44975P1030

Symbol

IMAB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$381.7m

Enterprise Value

$215.7m

Net debt

positive

Cash

$166.0m

Shares outstanding

188.0m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

P/B

1.9

Financial Health

Equity Ratio

94.4%

Return on Equity

-11.0%

ROCE

-18.7%

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

- | $-160.7m

EBIT

$-37.4m | $-42.7m

Net Income

$-37.7m | $-56.6m

Free Cash Flow

Growth (TTM | estimate)

Revenue

-100.0% | -

EBITDA

- | -216.8%

EBIT

70.2% | 16.2%

Net Income

56.7% | -157.1%

Free Cash Flow

EPS

$-0.2

FCF per Share

Short interest

0.9%

Employees

Rev per Employee

$0.0

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Get Started for Free Today

I-Mab - ADR Stock Analysis

Unlock Scores for Free

??

11 Analysts have issued a I-Mab - ADR forecast:

10x Buy

91%

More details on Analyst Estimates Including Price Targets

11 Analysts have issued a I-Mab - ADR forecast:

Buy

91%

Hold

Analyst Estimates with Stock Price Targets

Financial data from I-Mab - ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	24 24	46% 46% -
- Research and Development Expense	- -	- -
EBITDA	- -	- -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	-37 -37	70% 70% -
Net Profit	-38 -38	57% 57% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

I-Mab - ADR Stock News

Neutral

GlobeNewsWire

●

2 days ago

I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee

ROCKVILLE, Md., Aug. 25, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced the appointment of independent directors, Dr. Robert Lenz and Ms. Xin Liu, to its Board of Directors (the Board), effective as of August 22, 2025 and reiterated the a...

Neutral

GlobeNewsWire

●

6 days ago

I-Mab to Participate in September Investor Conferences

ROCKVILLE, Md., Aug. 21, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab's management team will participate in the following upcoming investor conferences in September, 2025:

Neutral

PRNewsWire

●

26 days ago

Everest Medicines Expands Strategic Investment in I-MAB

- Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash in I-Mab. Inclusive of I-MAB shares already held by Everest, the pro forma ownership will be 16.1%.

More I-Mab - ADR News

Company Profile

I-Mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders worldwide. It is developing TJ202, a CD38 antibody in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; TJ101, a long-acting human growth hormone that is in Phase II clinical trials to treat pediatric growth hormone deficiency; and TJ301, a IL-6 blocker in Phase II clinical trials for the treatment of ulcerative colitis and other autoimmune diseases. The company's product candidates in Phase I clinical trials include Enoblituzumab, a humanized B7-H3 antibody to treat immuno-oncology; TJ107, a long-acting recombinant human IL-7 to treat cancer treatment-related lymphopenia and cancer immunotherapy; TJC4, a CD47 monoclonal antibody with RBC-sparing differentiation; TJD5, a CD73 antibody for cancer treatment; and TJM2, a GM-CSF monoclonal antibody for rheumatoid arthritis and CAR-T-related therapies. Its product candidates in pre-clinical development comprise TJ210, an antibody targeting myeloid derived suppressor cells in cancers and autoimmune diseases; and TJX7, a novel CXCL13 antibody for autoimmune diseases. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

Head office	Cayman Islands
CEO	Xi-Yong Fu
Employees	32
Founded	2016
Website	www.i-mabbiopharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now